News

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

  • PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (recombinant human Interleukin-6 or rhIL-6) in CIPN will be presented in a poster session at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 5-10, in San Diego, California. Presentation details: Title: Low dose interleukin-6 (SON-080) for neuropathies: Toxicology and clinical plans Session Title: Pharmacology and Pharmacogenetics Presentation Type: Poster Session Date and Time: Wednesday April 10, 2024, 9:00 AM - 12:30 PM Abstract Number: 7181 Location: Poster Section 24 Poster Board Number: 22 About Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action.
    03/19/2024

Why Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today?

  • Sonnet BioTherapeutics (NASDAQ: SONN ) stock is falling on Wednesday after the biotechnology company revealed details of a public share offering. That public stock offering has Sonnet BioTherapeutics selling 2,843,750 shares of SONN stock at a price of $1.60 each.
    10/25/2023
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Sonnet BioTherapeutics Holdings, Inc. (SONN) can hold. Click on Rating Page for detail.

The price of Sonnet BioTherapeutics Holdings, Inc. (SONN) is 1.86 and it was updated on 2024-03-29 01:55:54.

Currently Sonnet BioTherapeutics Holdings, Inc. (SONN) is in undervalued.

News
    
News

7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole

  • Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
    Fri, Aug. 25, 2023

Why Is Sonnet BioTherapeutics (SONN) Stock Down 5% Today?

  • Sonnet BioTherapeutics (NASDAQ: SONN ) stock is taking a beating on Monday after the company announced a public stock offering. Investors will note that this public stock offering comes from selling stockholders and not directly from Sonnet BioTherapeutics.
    Mon, Jul. 31, 2023

Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference

  • PRINCETON, NJ / ACCESSWIRE / July 31, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that Pankaj Mohan, PhD, Founder and Chief Executive Officer, Jay Cross, Chief Financial Officer, and Richard Kenney, MD, Chief Medical Officer, will be presenting a corporate overview at the BTIG Virtual Biotechnology Conference, held August 7-8, 2023. Sonnet BioTherapeutics Fireside Chat Details: 2023 BTIG Virtual Biotechnology ConferenceDate: Monday, August 7, 2023Presentation Time: 12:00 pm ET Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the offering, the closing of the offering, the amount and anticipated use of proceeds from the offering, the timing of an IND submission, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.
    Mon, Jul. 31, 2023

Best Penny Stocks to Buy Under $1? 10 To Watch Now

  • Stocks that are priced below $5 per share are typically referred to as penny stocks. However, for the purpose of this article, we will be focusing specifically on penny stocks that are priced under $1.
    Thu, Jun. 22, 2023

Best Penny Stocks to Buy Under $1? 7 To Watch Now

  • Typically, we refer to stocks trading for less than $5 per share, as penny stocks. However, for this article, we're focusing specifically on penny stocks under $1.
    Fri, Jun. 16, 2023
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

Best Penny Stocks to Buy Under $1? 4 To Watch Now

  • Ever find yourself daydreaming about striking it rich in the stock market? Well, buckle up, because we're about to dive headfirst into the world of penny stocks under $1.
  • 06/15/2023

4 Penny Stocks To Watch Under $5 With Big News This Week

  • Everyone is looking for an edge to find penny stocks to buy before the masses. The difficult part of this is that many of these cheap stocks lack liquidity.
  • 05/26/2023

3 Hot Penny Stocks To Watch Under $1, Time To Buy?

  • Penny stocks under $1 to watch this week. The post 3 Hot Penny Stocks To Watch Under $1, Time To Buy?
  • 05/18/2023

Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting

  • PRINCETON, NJ / ACCESSWIRE / April 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share data from its SB101 clinical study with SON-1010 in oncology patients (NCT05352750) on Tuesday, April 18, 2023 at 5:00 pm ET. Webcast presenters will include: Richard Kenney, M.D.
  • 04/17/2023

Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting

  • PRINCETON, NJ / ACCESSWIRE / March 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from the company-sponsored SB101 multiple-dose clinical trial (NCT05352750) of SON-1010 (IL12-FHAB) in adult patients with advanced solid tumors will be presented in a poster session at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, in Orlando, Florida. Presentation details: Title: Clinical development of a novel form of interleukin-12 with extended pharmacokinetics Session Title: Phase I and First-in-Human Clinical Trials in Progress Presentation Type: Poster Session Date and Time: Tuesday April 18, 2023, 1:30 PM - 5:00 PM Abstract Number: CT245 Location: Poster Section 46 About Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific, bifunctional action.
  • 03/14/2023

5 Hot Penny Stocks To Watch This Week With Big News

  • Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 01/09/2023

Best Penny Stocks To Buy? 5 To Watch For November 2022

  • Penny stocks to watch this week. The post Best Penny Stocks To Buy?
  • 11/07/2022

Using Reddit to Find Penny Stocks to Buy? Use These Tips

  • Here's how to find penny stocks on Reddit right now The post Using Reddit to Find Penny Stocks to Buy? Use These Tips  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 11/02/2022

Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company's Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022

  • PRINCETON, NJ / ACCESSWIRE / November 1, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share initial clinical data from its SB101 clinical study with SON-1010 in oncology patients (NCT05352750) and its SB102 clinical study with SON-1010 in healthy volunteers (NCT05408572) on Wednesday, November 2, 2022 at 8:30 am ET. Webcast presenters will include:Richard Kenney, M.D.
  • 11/01/2022

How to Take Advantage of Market Volatility With Penny Stocks

  • Are these money making tips part of your penny stocks trading strategy? The post How to Take Advantage of Market Volatility With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 11/01/2022

Why Is Sonnet BioTherapeutics (SONN) Stock Up 100% Today?

  • The award for today's most impressive mover has to go to Sonnet BioTherapeutics (NASDAQ: SONN ). Currently, SONN stock has surged more than 120% on an intraday move that has seen this stock erase more than a month of losses.
  • 10/31/2022

Top Penny Stocks to Buy Now? 3 to Watch in July

  • Check these three penny stocks out for your watchlist right now The post Top Penny Stocks to Buy Now? 3 to Watch in July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 07/15/2022

Check These Penny Stocks For Your Watchlist This Week

  • Can these penny stocks climb this week? The post Check These Penny Stocks For Your Watchlist This Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 07/11/2022

Hot Penny Stocks to Buy in Mid-June 2022? 3 to Watch

  • Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy in Mid-June 2022?
  • 06/09/2022

Trending Penny Stocks to Buy This Month? 3 to Watch in April

  • Can these penny stocks continue to climb this month? The post Trending Penny Stocks to Buy This Month?
  • 04/17/2022

Best Penny Stocks To Buy Now? 7 Stocks Under $1 With Big News Today

  • Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?
  • 04/13/2022

Sonnet Shares Surge As FDA Clears Its First Human Trial For Solid Tumor Candidate

  • The FDA has signed off Sonnet BioTherapeutics Holdings Inc's (NASDAQ: SONN) Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) technology.  Sonnet will.
  • 03/16/2022

Trading Penny Stocks? Top Stock Market News for March 16th, 2022

  • What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for March 16th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 03/16/2022

Sonnet BioTherapeutics (SONN) Stock: Why The Price Fell

  • The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) fell by 4.57% in the most recent trading session. This is why it happened.
  • 02/09/2022

Top Penny Stocks to Buy This Week? 3 You Need to Watch

  • With October off to a great start for penny stocks, which small-caps are you watching? The post Top Penny Stocks to Buy This Week?
  • 10/04/2021

Penny Stocks That Will Explode? Check These 3 Out For Your List

  • Check these three penny stocks out for your September watchlist The post Penny Stocks That Will Explode? Check These 3 Out For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 09/15/2021

SONN Stock: Why It Significantly Increased Today

  • The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 20% pre-market. This is why it happened.
  • 09/15/2021

Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September

  • Red hot penny stocks to watch and YES all are under $1 right now. The post Best Penny Stocks To Buy Under $1 Right Now?
  • 09/03/2021

See Why Sonnet BioTherapeutics Stock Is Skyrocketing In Premarket Tuesday

  • ​​​​​Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock is soaring during premarket in reaction to the selection of SON-1410 as a development candidate for melanoma and renal cancers. SON-1410 represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the Company's Fully Human Albumin Binding (FHAB) platform.
  • 08/31/2021

SONN Stock: Over 60% Increase Pre-Market Explanation

  • The stock price of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 60% pre-market. This is why it happened.
  • 08/31/2021

Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)

  • SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs Selection of the asset was performed with input from Sonnet's Scientific Advisory Board An IND submission for SON-1410 is anticipated during the second half of 2022 PRINCETON, NJ / ACCESSWIRE / August 30, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has selected a novel development candidate after completing comparative studies in a mouse melanoma model. The candidate represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the company's Fully Human Albumin Binding (FHAB) platform.
  • 08/30/2021

Sonnet BioTherapeutics Stock Slumps After $30M Equity Raise

  • Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) priced the underwritten public offering of 35.3 million shares (including pre-funded warrants) and warrants to purchase up to 35.3 million shares.  Each share of common stock (or pre-funded warrant) has a combined price of $0.85, raising approximately $30.0 million gross proceeds.
  • 08/20/2021

Sonnet BioTherapeutics Shares Fall Over 45% Pre-Market: Why It Happened

  • The shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) fell over 45% pre-market. This is why it happened.
  • 08/20/2021

Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering

  • PRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 35,294,117 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 35,294,117 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase one share of common stock at a combined offering price of $0.85, for total gross proceeds of approximately $30.0 million, before underwriting discounts and commissions and offering expenses payable by Sonnet.
  • 08/19/2021

Buying Penny Stocks Right Now? 3 to Watch in 2021

  • Looking to buy penny stocks in 2021? Check these 3 out for your list The post Buying Penny Stocks Right Now?
  • 08/19/2021

SONN Stock: The Social Media Buzz Sending Sonnet Bio Rocketing Today

  • Sonnet BioTherapeutics (SONN) stock is taking off on Thursday and investors can thank retail traders on social media for pumping it higher. The post SONN Stock: The Social Media Buzz Sending Sonnet Bio Rocketing Today appeared first on InvestorPlace.
  • 08/19/2021

Sonnet BioTherapeutics Shares Increase Over 200% Pre-Market: Why It Happened

  • The shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) increased by over 200% pre-market. This is why it happened.
  • 08/19/2021

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update

  • Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update Expanded F H AB Intellectual Property Portfolio  Completed $15.9 million At-The-Market Financing  SON-1010 and SON-080 on track for IND submissions by calendar year end  PRINCETON, NJ / ACCESSWIRE / August 16, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended June 30th , 2021 and provided a business update. "Throughout the quarter, we've continued to make several advancements towards the clinic with our proprietary Fully Human Albumin Binding (F H AB) pipeline assets, and our partnered product" commented Pankaj Mohan, Ph.D.
  • 08/16/2021

Sonnet BioTherapeutics Announces Change in Date of Annual Meeting

  • Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ / ACCESSWIRE / June 14, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has changed the date of its upcoming annual meeting of stockholders (the "Annual Meeting") called for the purpose of approving certain proposals, including the election of directors and the ratification of the appointment of Sonnet's independent auditing firm for the fiscal year ended September 30, 2021, from June 24, 2021 to Thursday July 15, 2021 at 9:00 a.m.
  • 06/14/2021

Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology

  • U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
  • 06/08/2021

SONN Stock: Over 6% Increase Pre-Market Explanation

  • The stock price of Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) increased by over 6% pre-market. This is why it happened.
  • 05/10/2021

Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)

  • The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release syndrome. Pharmacokinetic (PK) analysis of serum samples confirmed an enhanced profile of IL12-FHAB over recombinant human IL-12, with a half-life around 40 hours in NHP.
  • 05/10/2021

SONN Stock: From $2.37 To $2.57 (8.44% Increase) Pre-Market Explanation

  • The stock price of Sonnet BioTherapeutics Holdings, Inc. (Nasdaq: SONN) increased from $2.37 to $2.57 (up 8.44%) pre-market. This is why it happened.
  • 05/03/2021

3 Penny Stocks With Huge Potential in May 2021

  • Penny stocks are back and better than ever; should you watch these 3 in May? The post 3 Penny Stocks With Huge Potential in May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 05/03/2021

Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics

  • New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories Upfront and potential milestone payments totaling up to $21 Million with up to 30% royalties on commercial sales NLT to fund Phase 1b/2a clinical trial and submit an IND planned for the second half of 2021 PRINCETON, NJ / ACCESSWIRE / May 3, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has executed a definitive agreement with New Life Therapeutics Pte. Ltd. (NLT ) of Singapore for the license of low-dose Interleukin 6, or IL-6, for the treatment of Diabetic Peripheral Neuropathy (DPN).
  • 05/03/2021

Hot Penny Stocks To Buy on Robinhood? Here's 4 To Watch

  • Top penny stocks on Robinhood? Here's 4 to check out for your May watchlist The post Hot Penny Stocks To Buy on Robinhood?
  • 04/30/2021

Sonnet BioTherapeutics Provides 2021 Business Update

  • PRINCETON, NJ / ACCESSWIRE / March 29, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today a business update on its ongoing programs. "Last year we continued execution across our pipeline, and I am excited to share an update on our ongoing activities," commented Pankaj Mohan, Ph.D.
  • 03/29/2021

Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations

  • PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca, as Head of Clinical Operations, effective March 22, 2021.
  • 03/22/2021

2 Falling Knives to Catch

  • Wall Street recommends buying shares of Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) and Sigma Labs Inc. (NASDAQ:SGLB), which you would not expect after these 2 stocks performed so poorly over the prior 52 weeks through Friday, and lost more than 59%. As a result of the sharp decline in the share price, these stocks are known as "falling knives.
  • 12/21/2020
Unlock
SONN Ratings Summary
SONN Quant Ranking